Logomix, Inc.

Logomix is a synthetic biology company pioneering next-generation human genome engineering. Its proprietary Geno-Writing™ platform enables the precise and efficient writing of megabase-scale genomic sequences in human cells, unlocking new possibilities in drug discovery, cell therapy, and regenerative medicine. By engineering super-functionalized cells with tailored genetic enhancements, Logomix is driving innovation in the development of advanced cell-based therapies for a wide range of diseases.